Detalhe da pesquisa
1.
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
J Transl Med
; 17(1): 391, 2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31771601